Vitamin D During Cancer Treatment

Česká verze

Authors: M. Tomíška ¹; Š. Novotná ¹; L. Klvačová ¹; J. Tůmová ²; A. Janíková ¹
Authors place of work: Interní hematologická a onkologická klinika LF MU a FN Brno ¹; Oddělení klinické biochemie, FN Brno ²
Published in the journal: Klin Onkol 2015; 28(2): 99-104
Category: Přehled
doi: https://doi.org/10.14735/amko201599

Summary

Recent knowledge on vitamin D has shown that its active form not only regulates calcium and phosphate metabolism but also has significant antimitotic and cell differentiation effects. It can inhibit proliferation, angiogenesis and metastatic potential in cancer tissue. Insufficient vitamin D plasma levels are found in 20– 60% of cancer patients at diagnosis. By many authors, vitamin D deficiency is associated with higher aggressivity of tumor and shorter survival of patients. Even in the absence of clinical studies showing benefit of supplementation on outcome, clear recommendations are currently available for treatment of vitamin D deficiency. Owing to the high prevalence of vitamin D insufficiency in cancer patients and significant risks of its further decrease after antitumor therapy, it should become standard of care to examine 25- hydroxyvitamin D serum levels and correct vitamin D insufficiency in cancer patients.

Key words:
vitamin D deficiency – 25-hydroxyvitamin D – neoplasms – prognosis

This study was supported by the grant for specific research MUNI/A/0723/2012.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
1. 11. 2014

Accepted:
27. 1. 2015

Zdroje

1. Cirmanová V, Kančeva R, Vondra K et al. Renesance vitamínu D. DMEV 2010; 13(3): 139– 145.

2. Matějovská Kubešová H, Tůmová J, Polcarová V et al. Vitamín D – připomínka známých a přehled méně známých skutečností. Vnitř Lék 2012; 58(3): 196– 201.

3. Víšek J, Kubišová M, Lášticová M et al. Komplexní účinky vitamínu D v lidském organismu. DMEV 2012; 15(4): 258– 263.

4. Toner CD, Davis CD, Milner JA. The vitamin D and cancer conundrum: aiming at a moving target. J Amer Dietol Association 2010; 110(10): 1492– 1500. doi: 10.1016/ j.jada.2010.07.007.

5. Bouillon R, Van Schoor NM, Gielen E et al. Optimal vitamin D status: a critical analysis on the basis of evidence‑based medicine. J Clin Endocrinol Metab 2013; 98(8): E1283– E1304. doi: 10.1210/ jc.2013‑ 1195.

6. Drábová K, Bienertová‑ Vašků J, Lokaj P et al. Vitamin D – jeho fyziologie, patofyziologie a význam v etiopatogernezi nádorových onemocnění. Čas Lék Česk 2013; 152(1): 20– 30.

7. Gocek E, Studzinski GP. Induction of differentiation in cancer cells by vitamin D: recognition and mechanisms. In: Trump DL, Johnson CS (eds). Vitamin D and cancer. Springer Science + Buisiness Media LLC 2011: 143– 173.

8. Cross HS. Vitamin D: synthesis and catabolism – considerations for cancer causation and therapy. In: Trump DL, Johnson CS (eds). Vitamin D and cancer. Springer Science + Buisiness Media LLC 2011: 1– 23.

9. Krishnan AV, Feldman D. Anti‑inflammatory activity of calcitriol in cancer. In: Trump DL, Johnson CS (eds). Vitamin D and cancer. Springer Science + Buisiness Media LLC 2011: 53– 71.

10. Hollis BW. Assessment of vitamin D status in the 21th century. In: Trump DL, Johnson CS (eds). Vitamin D and cancer. Springer Science + Buisiness Media LLC 2011: 327– 338.

11. Teleni L, Baker J, Koczwara B et al. Clinical outcomes of vitamin D deficiency and supplementation in cancer patients. Nutrition Reviews 2013; 71(9): 611– 621. doi: 10.1111/ nure.12047.

12. Schottker B, Haug U, Schomburg L et al. Strong associations of 25- hydroxyvitamin D concentrations with all‑cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr 2013; 97(4): 782– 793. doi: 10.3945/ ajcn.112.047712.

13. Zhou W, Heist RS, Liu G et al. Circulating 25– hydroxyvitamin D levels predict survival in early‑stage non‑small‑cell lung cancer patients. J Clin Oncol 2007; 25(5): 479– 485.

14. Goodwin P, Ennis M, Pritchard KI et al. Prognostic effects of 25- hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27(23): 3757– 3763. doi: 10.1200/ JCO.2008.20.0725.

15. Shanafelt TD, Drake MT, Maurer MJ et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 2011; 117(5): 1492– 1498. doi: 10.1182/ blood‑ 2010‑ 07‑ 295683.

16. Ng K, Sargent DJ, Goldberg RM et al. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup Trial N9741. J Clin Oncol 2011; 29(12): 1599– 1606. doi: 10.1200/ JCO.2010.31.7255.

17. Giovannucci E. The epidemiology of vitamin D and cancer risk. In: Trump DL, Johnson CS (eds). Vitamin D and cancer. Springer Science + Buisiness Media LLC 2011: 73– 96.

18. Ma Y, Zhang P, Wang F et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011; 29(28): 3775– 3782. doi: 10.1200/ JCO.2011.35.7566.

19. Zgaga L, Agakov F, Theodoratou E et al. Model selection approach suggests causal association between 25- hydroxyvitamin D and colorectal cancer. PLoS One 2013; 8(5): e63475. doi: 10.1371/ journal.pone.0063475.

20. Liu SL, Zhao YP, Dai MH et al. Vitamin D status and the risk of pancreatic cancer: a meta‑analysis. Chin Med J 2013; 126(17): 3356– 3359.

21. Orell‑ Kotikangas H, Schwab U, Osterlund P et al. High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis. Head Neck 2012; 34(10): 1450– 1455. doi: 10.1002/ hed.21954.

22. Lee HJ, Muindi JR, Tan W et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer 2014; 120(4): 521– 529. doi: 10.1002/ cncr.28368.

23. Tretli S, Schwartz GG, Torjesen PA et al. Serum levels of 25- hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population‑based study. Cancer Causes Control 2012; 23(2): 363– 370. doi: 10.1007/ s10552‑ 011‑ 9885‑ 6.

24. Heist RS, Zhou W, Wang Z et al. Circulating 25- hydroxyvitamin D, VDR polymorphisms and survival in advanced non‑small‑cell lung cancer. J Clin Oncol 2008; 26(34): 5596– 5602. doi: 10.1200/ JCO.2008.18.0406.

25. Mohr SB, Gorham ED, Kim J et al. Meta‑analysis of vitamin D sufficiency improving survival of patients with breast cancer. Anticancer Research 2014; 34(3): 1163– 1166.

26. Holt SK, Kolb S, Fu R et al. Circulating levels of 25- hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol 2013; 37(5): 666– 670. doi: 10.1016/ j.canep.2013.07.005.

27. Drake MT, Maurer MJ, Link BK et al. Vitamin D insufficiency and prognosis in non‑Hodgkin’s lymphoma. J Clin Oncol 2010; 28(27): 4191– 4198. doi: 10.1200/ JCO.2010.28.6674.

28. Bittenbring JT, Achenbach M, Altmann B et al. Inferior outcome of elderly DLBCL patients with 25- OH vitamin D deficiency treated with CHOP plus rituximab (R): results of the RICOVER‑ 60 trial of the German High‑Grade non‑Hodgkin Lymphoma Study Group (DSHNHL). Hematol Oncol 2013; 31 (Suppl 1): 130– 131.

29. Tomiska M, Novotna S, Charouzkova J et al. Vitamin D insufficiency is not associated with disease aggressivity in newly diagnosed non‑Hodgkin lymphoma patients. Hematol Oncol 2013; 31 (Suppl 1): 213.

30. Boullata JI. A rational approach to vitamin D supplementation. Nutrition 2012; 28(11– 12): 1204– 1205. doi: 10.1016/ j.nut.2012.08.002.

31. Obermannová R, Demlová R, Drábová K et al. Vitamín D jako významný steroidní hormon u karcinomu prsu. Klin Onkol 2014; 27 (Suppl 1): S143– S149. doi: 10.14735/ amko2014S143.

32. Kennel KA, Drake MT. Vitamin D in the cancer patient. Curr Opin Support Palliat Care 2013; 7(3): 272– 277. doi: 10.1097/ SPC.0b013e3283640f74.